On June 7, 2022, Raymond Cheong, M.D., Ph.D., notified Talis Biomedical Corporation (the “Company”) of his resignation from his position as a member of the Company's Board of Directors (the “Board”) and as a member of the Science, Technology and Clinical Affairs Committee of the Board, effective immediately prior to the Company's 2022 Annual Meeting of the Stockholders held on June 10, 2022 (the “Annual Meeting”). Dr. Cheong's departure is to ensure the Company's continued compliance with Nasdaq Listing Rule 5605(b), which requires that a majority of the Board be comprised of independent directors (as defined in Nasdaq Listing Rule 5605(a)(2)) and is not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.